SubHero Banner

Bayer announces decision to withdraw Aliqopa® (copanlisib)

November 13, 2023 - Bayer announced that following discussions with the FDA, it will withdraw the Aliqopa (copanlisib) New Drug Application for adult patients with relapsed follicular lymphoma (FL) who have received at least two prior systemic therapies. A confirmatory clinical trial did not meet the primary endpoint of progression-free survival (PFS) benefit vs. standard immunotherapy.

Download PDF